Skin cancer risk in epidermolysis bullosa patients using Filsuvez
Part of Genetic & congenital, Skin clinical trials.
This study tracks anyone with dystrophic or junctional epidermolysis bullosa who is using Filsuvez gel to see how often skin cancers appear. It is designed to understand the long-term safety of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of either dystrophic or junctional epidermolysis bullosa (a condition that makes skin very fragile).
- This study is looking at whether people using Filsuvez (a gel that helps wounds heal) might have a higher or lower risk of skin cancer.
- There are no other restrictions—most people with this type of EB can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called oleogel-S10 on wounds caused by a rare skin condition called epidermolysis bullosa (EB). It is only for people of Japanese descent who have a specific type of EB called junctional or dystrophic EB. The gel is put on the wound to help it heal.
This trial tests a gel called Filsuvez on skin blisters and sores caused by epidermolysis bullosa simplex (EBS), a condition where skin is very fragile. The gel may help wounds heal faster and reduce pain.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
This trial tests a gene therapy called BVEC to see if it can prevent squamous cell carcinoma (a type of skin cancer) from coming back in people with a severe form of epidermolysis bullosa (fragile skin). It is for adults who have had a confirmed SCC and are willing to use the gene therapy.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
Hear when a new Epidermolysis Bullosa, Dystrophic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.